Clinical Trials Logo

Filter by:
NCT ID: NCT05032053 Recruiting - Ischemic Stroke Clinical Trials

Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

AIM-2
Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.

NCT ID: NCT05032027 Recruiting - Clinical trials for Pelvic Cancer, Enteritis, Probiotics,Chemoradiotherapy

Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy

probiotics
Start date: August 27, 2021
Phase: N/A
Study type: Interventional

Effect of Probiotics on Raditon Enteritis in Pelvic Tumor Patients Receiving Radiotherapy.

NCT ID: NCT05032014 Recruiting - Liver Cancer Clinical Trials

Probiotics Enhance the Treatment of PD-1 Inhibitors in Patients With Liver Cancer

Start date: November 19, 2021
Phase: N/A
Study type: Interventional

Human microbes have been called "the second genome of humanity".On May 13,2016,the White House launched the National Microbiome Initiative (NMI), with an estimated investment of us $521 million, to elevate microbiome research to a national strategic status. The gut is the largest microecological environment in the human body. The research in the field of intestinal microbiome has become one of the most advanced and hot research directions in the scientific field of the world today. At present, more than 50 diseases have been found to be related to intestinal microbiome disorders. Pd-1 (programmed death receptor 1) is an important immunosuppressive molecule.It regulates the immune system and promotes tolerance by down-regulating the immune system's response to human cells and by suppressing T cell inflammatory activity. In the past, the research team and colleagues in related fields have found a strong correlation between Gut Microbiome and the efficacy of anti-PD-1 immunotherapy in cancer patients.This protects against autoimmune diseases, but it also prevents the immune system from killing cancer cells. As more and more scientific evidence shows that intervention of human intestinal flora may improve the efficacy of anti-PD-1 immunotherapy in tumor patients, intestinal flora, as the most effective way to intervene human intestinal flora, has been mentioned by many research institutions and international drug manufacturers in combination with anti-PD-1.Our previous study showed that the abundance of beneficial bacteria such as lactic acid bacteria, bifidobacteria and Akkermansia Muciniphila was significantly correlated with pD-1 inhibitor response, and regulating the intestinal flora content could improve the effect of PD-1 inhibitor on mouse tumors, indicating that microbial flora was involved in regulating cancer immunotherapy.

NCT ID: NCT05031949 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-Resectable

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

CCGLC-003
Start date: October 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.

NCT ID: NCT05031533 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Dose-painting Radiation for LA-NSCLC

DPRLC
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer.

NCT ID: NCT05030779 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Start date: September 10, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

NCT ID: NCT05030519 Recruiting - Breast Cancer Clinical Trials

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Start date: January 18, 2021
Phase:
Study type: Observational

By measuring the intestinal flora abundance and bacterial count of patients in the early stage of using pyrotinib to clarify the relationship between diarrhea caused by pyrotinib and changes in intestinal flora in breast cancer patients, the correlation between the change of intestinal flora and the relief of diarrhea are also explored after two-cycle treatment.

NCT ID: NCT05030259 Recruiting - Clinical trials for Acute Compartment Syndrome

The Research About the ACS After Femoropopliteal Arterial Injuries

Start date: September 1, 2021
Phase:
Study type: Observational

Crural Compartment syndrome is a well-known sequela after femoropopliteal arterial injuries in the lower extremity, particularly when there has been a long period of ischemia,need for ligation of a major vein, or when there is severe associated soft tissue.There is conteoversy in the treatment.

NCT ID: NCT05030246 Recruiting - Clinical trials for Primary Peritoneal Cancer

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Start date: July 14, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Surufatinib combined with Toripalimab in patients with peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer.

NCT ID: NCT05030064 Recruiting - Ulcerative Colitis Clinical Trials

Clinical Study on the Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis With Depression

Start date: September 10, 2021
Phase: N/A
Study type: Interventional

This is a single-center trial, randomized, single-blind, placebo-controlled clinical intervention study which intends to explore the safety and effectiveness of FMT capsule for the treatment of ulcerative colitis with depression.